Drug Search Results
More Filters [+]

PEG-BCT-100

Alternative Names: peg-bct-100, pegbct100, peg bct 100, PEG- BCT-100, rhArg1peg5000
Latest Update: 2022-09-02
Latest Update Note: Clinical Trial Update

Product Description

pegylated recombinant human arginase for children and young people with relapsed/refractory leukaemia, neuroblastoma, sarcoma and high grade gliomas (brain cancers). (Sourced from: https://clinicaltrials.gov/ct2/show/NCT03455140)

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: Coagulation Factor

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Bio-Cancer Treatment International Limited
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for PEG-BCT-100

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Hepatocellular Carcinoma|Glioma|Brain Cancer|Leukemia|Neuroblastoma|Sarcoma|Acute Myeloid Leukemia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

PARC

P2

Completed

Acute Myeloid Leukemia

2022-07-22

PARC

P2

Unknown status

Sarcoma|Glioma|Leukemia|Neuroblastoma|Brain Cancer

2021-05-01

BCT-100-007

P2

Unknown status

Acute Myeloid Leukemia

2019-09-01

BCT-100-006

P2

Completed

Hepatocellular Carcinoma

2017-03-01

55%

Recent News Events